Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090266 · ClinicalTrials.gov registry record · Phase 1
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
A Phase 1 study of Cancer and Non-Small Cell Lung Cancer, sponsored by OncoResponse.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
- 4
- Study locations
NCT06090266: Recruiting Phase 1 study of Cancer and Non-Small Cell Lung Cancer, sponsored by OncoResponse.
NCT06090266 is a Phase 1 study of Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by OncoResponse. The registered enrollment target is 168 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090266, a Phase 1 study of Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by OncoResponse.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.
Primary Outcome
The incidence of DLTs during the DLT assessment period.
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG OR502
Study Locations (4)
Texas
- NEXT Austin - Austin
- NEXT Dallas - Irving
- NEXT Oncology - San Antonio
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 1 |
What NCT06090266 shows while recruiting
NCT06090266 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).
The record links to 7 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06090266 reports a single indexed study location in Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT06090266 about?
NCT06090266 is a clinical study titled "A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents". This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjec...
What is the current status of trial NCT06090266?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2023-10-24. Estimated completion is 2027-02-01.
What conditions does trial NCT06090266 study?
This clinical trial studies the following conditions: Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Cancer, Malignant Neoplasm.
What interventions are being tested in trial NCT06090266?
The interventions under investigation include: Cemiplimab (DRUG), OR502 (DRUG).
Who is sponsoring clinical trial NCT06090266?
This trial is sponsored by OncoResponse, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06090266 being conducted?
This trial has 4 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06090266's enrollment target sits among peer trials
168 255th of 615 higher than 361 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI